<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0484-7903</journal-id>
<journal-title><![CDATA[Revista mexicana de anestesiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. anestesiol.]]></abbrev-journal-title>
<issn>0484-7903</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Anestesiología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0484-79032024000200102</article-id>
<article-id pub-id-type="doi">10.35366/115317</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Sufentanyl: una opción al paradigma clásico]]></article-title>
<article-title xml:lang="en"><![CDATA[Sufentanyl: an option to the classic paradigm]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barrientos-Aderwald]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez-Rodríguez]]></surname>
<given-names><![CDATA[Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Contreras-Martínez]]></surname>
<given-names><![CDATA[Óscar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Villasana]]></surname>
<given-names><![CDATA[Irais]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Ángeles Metropolitano Departamento de Anestesiología ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Hospital Ángeles Metropolitano ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Ángeles Metropolitano Departamento de Anestesiología ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Ángeles Metropolitano  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2024</year>
</pub-date>
<volume>47</volume>
<numero>2</numero>
<fpage>102</fpage>
<lpage>107</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0484-79032024000200102&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0484-79032024000200102&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0484-79032024000200102&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  los opioides forman parte del manejo anestésico desde tiempos remotos. El desarrollo de nuevos fármacos a partir del fentanilo dio como resultado opioides más potentes y específicos. El sufentanyl se presenta como una opción más para el manejo anestésico perioperatorio, en diferentes escenarios clínicos, como anestesia general, sedación o adyuvante; el margen terapéutico amplio, la potencia analgésica y los efectos adversos predecibles lo presentan como una opción equiparable y en algunos casos superior a otros opioides como el fentanilo. Las dosis referidas por la Food and Drug Administration (FDA) y algunos artículos son amplias, en una gran variedad de situaciones la orientación a la dosificación mínima efectiva es la más recomendada.  Objetivo:  presentar una revisión de los aspectos farmacocinéticos y farmacodinámicos del sufentanyl, sus propiedades farmacológicas, aplicaciones y recomendaciones basadas en la literatura y la práctica clínica. Aportar difusión del conocimiento y uso del sufentanyl para fomentar un cambio en el paradigma clásico del uso de opioides en anestesia.  Conclusiones:  El sufentanil es una de las mejores opciones para el manejo del dolor en distintos escenarios clínicos, desde procedimientos de corta duración como las sedaciones hasta cirugías de gran complejidad, su perfil farmacocinético muy similar al fentanilo, con un amplio margen terapéutico y mayor potencia analgésica, lo convierten en una opción más que adecuada para la práctica anestésica contemporánea.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  since ancient times opioids have been part of anesthesia. The development of new drugs based on the piperidine class prototype fentanyl has resulted in more potent and specific opioids. One such example is sufentanil. Sufentanil is presented as a further option for perioperative anesthetic management in different clinical scenarios from general anesthesia to sedation or critical care. Its wide therapeutic range, analgesic potency and predictable adverse effects make it a comparable or superior option to other opioids like fentanyl. The dosage recommended by the FDA and other sources are broad but in a wide variety of situations opting for the minimum effective dosage is the most recommended.  Objective:  a review of the pharmacokinetic and pharmacodynamic aspects of sufentanil, its applications and recommendations based on literature and clinical practice. To spread knowledge of the clinical use of sufentanil in order to promote a change in the classical paradigm of opioid use in anesthesia.  Conclusions:  Sufentanil is one of the best options for pain management in different clinical scenarios, from short-term procedures such as sedations to highly complex surgeries, its pharmacokinetic profile very similar to fentanyl, with a wide therapeutic margin and greater analgesic potency, make it a more than adequate option for contemporary anesthetic practice.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[opioides]]></kwd>
<kwd lng="es"><![CDATA[sufentanyl]]></kwd>
<kwd lng="es"><![CDATA[dosificación farmacocinética]]></kwd>
<kwd lng="es"><![CDATA[farmacodinamia]]></kwd>
<kwd lng="en"><![CDATA[opioids]]></kwd>
<kwd lng="en"><![CDATA[sufentanil]]></kwd>
<kwd lng="en"><![CDATA[pharmacokinetic dosing]]></kwd>
<kwd lng="en"><![CDATA[pharmacodynamics]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brook]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Bennett]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The chemical history of morphine: an 8000-year journey, from resin to de-novo synthesis]]></article-title>
<source><![CDATA[J Anesth Hist]]></source>
<year>2017</year>
<volume>32</volume>
<page-range>50-5</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maciejewski]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sufentanil in anaesthesiology and intensive therapy]]></article-title>
<source><![CDATA[Anaesthesiol Intensive Ther]]></source>
<year>2012</year>
<volume>44</volume>
<page-range>35-41</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dayer]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Painter]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[McCain]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cullen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A recent history of opioid use in the US: Three decades of change]]></article-title>
<source><![CDATA[Subst Use Misuse]]></source>
<year>2019</year>
<volume>54</volume>
<page-range>331-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leysen]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Gommeren]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Niemegeers]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[[3H]Sufentanil, a superior ligand for mu-opiate receptors: binding properties and regional distribution in rat brain and spinal cord]]></article-title>
<source><![CDATA[Eur J Pharmacol]]></source>
<year>1983</year>
<volume>87</volume>
<page-range>209-25</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gropper]]></surname>
<given-names><![CDATA[MMA]]></given-names>
</name>
<name>
<surname><![CDATA[Neal]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lars]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Eriksson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fleisher]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kate Leslie]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<source><![CDATA[Miller anestesia. Vol I-II]]></source>
<year>2021</year>
<edition>9th</edition>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harkouk H]]></surname>
<given-names><![CDATA[Pares F]]></given-names>
</name>
<name>
<surname><![CDATA[Daoudi K]]></surname>
<given-names><![CDATA[Fletcher]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farmacología de los opioides]]></article-title>
<source><![CDATA[EMC-Anestesia-Reanimación]]></source>
<year>2018</year>
<volume>44</volume>
<page-range>1-24</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[XM]]></given-names>
</name>
<name>
<surname><![CDATA[Duan]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients]]></article-title>
<source><![CDATA[Chin Med J]]></source>
<year>2009</year>
<volume>122</volume>
<page-range>291-5</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scholz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Steinfath]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schulz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update]]></article-title>
<source><![CDATA[Clin Pharmacokinet]]></source>
<year>1996</year>
<volume>31</volume>
<page-range>275-92</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stanley]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The history and development of the fentanyl series]]></article-title>
<source><![CDATA[J Pain Symptom Manage]]></source>
<year>1992</year>
<volume>7</volume>
<page-range>S3-7</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Farré]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farmacología de los opioides]]></article-title>
<source><![CDATA[Adicciones]]></source>
<year>2005</year>
<volume>17</volume>
<page-range>21-40</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cardoso-Ortiz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[López-Luna]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Lor]]></surname>
<given-names><![CDATA[KB]]></given-names>
</name>
<name>
<surname><![CDATA[Cuevas-Flores]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Flores de la Torre]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Covarrubias]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farmacología y epidemiología de opioides]]></article-title>
<source><![CDATA[Revista Bio Ciencias]]></source>
<year>2020</year>
<volume>7</volume>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[MCS]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[GIP]]></given-names>
</name>
<name>
<surname><![CDATA[Carranza]]></surname>
<given-names><![CDATA[ACJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El tratamiento del dolor y los opioides]]></article-title>
<source><![CDATA[Ciencia]]></source>
<year>2020</year>
<volume>71</volume>
<page-range>52-61</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sebel]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Barrett]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Kirk]]></surname>
<given-names><![CDATA[CJC]]></given-names>
</name>
<name>
<surname><![CDATA[Heykants]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transdermal absorption of fentanyl and sufentanil in man]]></article-title>
<source><![CDATA[European Journal of Clinical Pharmacology]]></source>
<year>1987</year>
<volume>32</volume>
<page-range>529-31</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zou]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ling]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kong]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of a small priming dose of sufentanil on sufentanil-induced cough]]></article-title>
<source><![CDATA[J Perianesth Nurs]]></source>
<year>2020</year>
<volume>35</volume>
<page-range>661-4</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<source><![CDATA[Highlights of prescribing information]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="">
<collab>Fda, Cder</collab>
<source><![CDATA[Highlights of prescribing information]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lehmann&#8217;]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Sipakis&#8217;]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gasparin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Van Peer&#8217;]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetics of sufentanil in general surgical patients under different conditions of anaesthesia]]></article-title>
<source><![CDATA[Acta Anaesthesiol Scand]]></source>
<year>1993</year>
<volume>37</volume>
<page-range>176-80</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gepts]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Shafer]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Camu]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linearity of pharmacokinetics and model estimation of sufentanil]]></article-title>
<source><![CDATA[Anesthesiology]]></source>
<year>1995</year>
<volume>83</volume>
<page-range>1194-204</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barash]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Cullen]]></surname>
<given-names><![CDATA[BF]]></given-names>
</name>
<name>
<surname><![CDATA[Stoelting]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Cahalan]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Stock]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Núria]]></surname>
<given-names><![CDATA[Llavina]]></given-names>
</name>
</person-group>
<source><![CDATA[Anestesia clínica]]></source>
<year>2017</year>
<edition>8a</edition>
<publisher-name><![CDATA[Wolters Kluwer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Conti]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Arcangeli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Antonelli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sedation with sufentanil in patients receiving pressure support ventilation has no effects on respiration: a pilot study]]></article-title>
<source><![CDATA[Can J Anaesth]]></source>
<year>2004</year>
<volume>51</volume>
<page-range>494-9</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[El Tahan]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Khidr]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low target sufentanil effect-site concentrations allow early extubation after valve surgery]]></article-title>
<source><![CDATA[J Cardiothorac Vasc Anesth]]></source>
<year>2013</year>
<volume>27</volume>
<page-range>63-70</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Slepchenko]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Goubaux]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Levron]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Le Moing]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Raucoules-Aimé]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Performance of target-controlled sufentanil infusion in obese patients]]></article-title>
<source><![CDATA[Anesthesiology]]></source>
<year>2003</year>
<volume>98</volume>
<page-range>65-73</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[XY]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[XM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[[Effect of target-controlled infusion sufentanil in different doses combined with nitrogen monoxide inhalation on hemodynamics and postoperative recovery]]]></article-title>
<source><![CDATA[Zhonghua Yi Xue Za Zhi]]></source>
<year>2007</year>
<volume>87</volume>
<page-range>3325-8</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparing the pain of propofol via different combinations of fentanyl, sufentanil or remifentanil in gastrointestinal endoscopy]]></article-title>
<source><![CDATA[Acta Cir Bras]]></source>
<year>2014</year>
<volume>29</volume>
<page-range>675-80</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Formulary drug review: sufentanil sublingual]]></article-title>
<source><![CDATA[Hosp Pharm]]></source>
<year>2019</year>
<volume>54</volume>
<page-range>222-8</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corder]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Bruchas]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Scherrer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Endogenous and exogenous opioids in pain]]></article-title>
<source><![CDATA[Annu Rev Neurosci]]></source>
<year>2018</year>
<volume>41</volume>
<page-range>453-73</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hua]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances in nanoparticulate drug delivery approaches for sublingual and buccal administration]]></article-title>
<source><![CDATA[Front Pharmacol]]></source>
<year>2019</year>
<volume>10</volume>
<page-range>1328</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van de Donk]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ward]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Langford]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Dahan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetics and pharmacodynamics of sublingual sufentanil for postoperative pain management]]></article-title>
<source><![CDATA[Anaesthesia]]></source>
<year>2018</year>
<volume>73</volume>
<page-range>231-7</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koushik]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Cherkalin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sankar]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Shaparin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Viswanath]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A review of sublingual sufentanil tablet (SST) and its utility as an analgesic agent for pain procedures]]></article-title>
<source><![CDATA[Curr Pain Headache Rep]]></source>
<year>2022</year>
<volume>26</volume>
<page-range>145-9</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 90% effective dose of sufentanil for epidural analgesia in the early first stage of labor: a double-blind, sequential dose-finding study]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year>2021</year>
<volume>43</volume>
<page-range>1191-200</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vyas]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Sahu]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Parampill]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative study of intrathecal sufentanil bupivacaine versus intrathecal bupivacaine in patients undergoing elective cesarean section]]></article-title>
<source><![CDATA[J Anaesthesiol Clin Pharmacol]]></source>
<year>2010</year>
<volume>26</volume>
<page-range>488-92</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gong]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of ropivacaine plus sufentanil and ropivacaine plus dexmedetomidine for labor epidural analgesia: a randomized controlled trial protocol]]></article-title>
<source><![CDATA[Medicine (Baltimore)]]></source>
<year>2020</year>
<volume>99</volume>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karasawa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Iwanov]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Moulds]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sufentanil and alfentanil cause vasorelaxation by mechanisms independent of the endothelium]]></article-title>
<source><![CDATA[Clin Exp Pharmacol Physiol]]></source>
<year>1993</year>
<volume>20</volume>
<page-range>705-11</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hofbauer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tesinsky]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hammerschmidt]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[No reduction in the sufentanil requirement of elderly patients undergoing ventilatory support in the medical intensive care unit]]></article-title>
<source><![CDATA[Eur J Anaesthesiol]]></source>
<year>1999</year>
<volume>16</volume>
<page-range>702-7</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wappler]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Scholz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Prause]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mollenberg]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Bause]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Schulte am Esch]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stufenkonzept zur Analgosedierung in der Intensivmedizin mit Sufentanil [Level concept of analgesic dosing in intensive care medicine with sufentanil]]]></article-title>
<source><![CDATA[Anasthesiol Intensivmed Notfallmed Schmerzther]]></source>
<year>1998</year>
<volume>33</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>8-26</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ethuin]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Boudaoud]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Leblanc]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients]]></article-title>
<source><![CDATA[Intensive Care Med]]></source>
<year>2003</year>
<volume>29</volume>
<page-range>1916-20</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nies]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pfister]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Monitoring of sedation depth in intensive care unit by therapeutic drug monitoring? A prospective observation study of medical intensive care patients]]></article-title>
<source><![CDATA[J Intensive Care]]></source>
<year>2018</year>
<volume>6</volume>
<page-range>62</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
